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Abstracts / Biol Blood Marrow Transplant 21 (2015) S30eS53S443.1 x 106/kg (range 1.1-7.5) & CD3+ cell dose was 1.5 x 103/kg
(range 0.3-13.7). One pt died early post-transplant. In 38
evaluable pts, 37/38 (97%) recovered neutrophils (median day
13, range 11-38) whereas 1/38 with donor-speciﬁc HLA-Abs
(DSA) to the haplo & both CB units had haplo/CB rejection.
Additionally, one of the 37 pts with early neutrophil recovery
had haplo rejection & CB graft failure in the setting of very
low dominant CB unit CD34+ cell dose. The remaining 36 pts
had both sustained CB engraftment & universal haplo-rejec-
tion as follows (examples in Figure): 20/36 (56%) pts had a
haplo-bridge without recurrent neutropenia (Fig. A), 5/36
(14%) had transient haplo-engraftment with second nadir
(Fig. B), & 11/36 (30%) had no haplo-engraftment & delayed
CB-mediated neutrophil recovery (median 26 days, range
15-33, Fig. C). Haplo rejection & sustained CB engraftment
was associated with dominant unit-derived peripheral
blood T-cells (detected day +28). There was no association
between the haplo-bridge duration & the haploCD34+ cell
dose (above a dose of 2.0 x 106/kg) or the haplo-dominant
CB unit HLA-match (median 3/8). 29/38 (76%) pts
developed pre-engraftment syndrome (PES, median onsetday 10, range 7-15). PES was severe in 3/38 (8%) pts but all
resolved with corticosteroids.
Conclusions: DCBT-haploCD34+ is feasible in most pts &
neutrophil engraftment is enhanced. However, the haplo-
bridge is not guaranteed & given the haplo-graft can be
rapidly rejected the quality & dose of the CB unit(s) is critical.
Low haplo-graft dose & haplo-DSA are likely relevant in
haplo engraftment whereas the dominant CB unit-haplo
HLA-mismatch is not (possibly due to the high degree of
mismatch observed between all haplo & CB grafts). Finally,
PES is common after DCBT-haplo, may be severe, & requires
early corticosteroid therapy.
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Allogeneic hematopoietic stem cell transplantation (HSCT)
can cure SCD but chemotherapy-based conditioning regi-
mens are associated with substantial morbidity and mor-
tality, particularly in adult patients. A chemotherapy-free,
non-myeloablative HSCT with alemtuzumab 1mg/kg divided
over 5 days followed by total body irradiation (TBI) 300cGy
was recently developed at the National Institutes of Health
and obtained stable mixed chimerism and clinical cure in
90% of SCD patients receiving an HLA and ABO-matched,
related HSCT. The same study was replicated in high risk SCD
adult patients at the University of Illinois at Chicago.
Thirteen patients aged 17 - 40 years were transplanted be-
tween November 2011 and June 2014. Indications included
3 vaso-occlusive crises (VOC) per year (n¼7), stroke (n¼4)
and >1 episode of acute chest syndrome (ACS) requiring
intensive care (n¼2). Unmanipulated, G-CSF mobilized pe-
ripheral blood cells were collected from HLA-matched,
related donors (MRD) with Hb AS (n¼4) or Hb AA (n¼9). Four
patients had red blood cell (RBC) alloimmunization and 2/13
patients received a graft withmajor ABO incompatibility. The
median number of CD34+ cells infused was 8.1 x 106 cells/kg.
Of 13 patients, 10 had severe neutropenia for a median
duration of 5 days (range: 1 - 14) and 3 patients had a plateletFigure.count < 50 x109/L requiring a platelet transfusion. All pa-
tients engrafted and are alivewith amedian follow-up of 402
days (range: 118e1051). Cytokine levels involved in T-cell
regulation (IL-5, IL-10, and IL-13) increased post-alemtuzu-
mab compared to pre-HSCT levels while no differences were
observed in IL-2, IL-4, IL-12 or TNF-a. One secondary graft
failure occurred in a patient not compliant with sirolimus
and no acute or chronic GVHD has been observed. The me-
dian donor chimerism at 1 and 6 months was 96% (range:
63e98%) and 84% (range: 41e96%), respectively, in blood
mononuclear cells; and 48% (range: 20e97%) and 25%
(range: 20 e 48%), respectively, in CD3+ T cells (Figure 1A).
Median hemoglobin concentration increased from 8.4 g/dL
(range: 6.6e12.4 g/dL) to 12.9 g/dL (range: 11.0e16.8 g/dL)
and the median reticulocyte percentage decreased from
12.1% (range: 4.8 e 19.6%) to 1.9% (range: 1.3e6.2%). Changes
in hemoglobin fractionation in HSCT recipients from Hb AA
donors are shown in Figure 1B. No episodes of ACS or stroke
have been observed following hospital discharge after HSCT.
Two patients have been tapered off of sirolimus with stable
chimerisms, laboratory values, and no repeat episodes of
SCD-related complications.
Non-myeloablative HSCT from MRD with alemtuzumab and
TBI in SCD adult patients provides a clinical cure in the ma-
jority of patients with low toxicity and no transplant-related
mortality.
